KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Invested Capital (2016 - 2025)

Biomarin Pharmaceutical's Invested Capital history spans 17 years, with the latest figure at $6.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 7.58% year-over-year to $6.1 billion, compared with a TTM value of $6.1 billion through Dec 2025, up 7.58%, and an annual FY2025 reading of $6.1 billion, up 7.58% over the prior year.
  • Invested Capital for Q4 2025 was $6.1 billion at Biomarin Pharmaceutical, up from $6.1 billion in the prior quarter.
  • The five-year high for Invested Capital was $6.1 billion in Q4 2025, with the low at $4.2 billion in Q1 2021.
  • Average Invested Capital over 5 years is $5.1 billion, with a median of $4.8 billion recorded in 2023.
  • Year-over-year, Invested Capital dropped 2.69% in 2021 and then rose 20.87% in 2024.
  • Tracing BMRN's Invested Capital over 5 years: stood at $4.3 billion in 2021, then increased by 6.71% to $4.6 billion in 2022, then rose by 18.3% to $5.4 billion in 2023, then grew by 3.9% to $5.7 billion in 2024, then grew by 7.58% to $6.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Invested Capital are $6.1 billion (Q4 2025), $6.1 billion (Q3 2025), and $6.0 billion (Q2 2025).